Key facts
- Bold Therapeutics’s last known valuation is $140.0M.
- It has raised $25.0M across 1 recorded rounds; the latest was Early Stage VC ($5.5M) in Jul 2018.
- Notable investors include Life Sciences BC, Gaston Capital, National Research Council Canada, Tampa Bay Technology Incubator.
- Bold Therapeutics has filed 1 Form D with the SEC, most recently Feb 2021 ($5.5M sold to 48 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Bold Therapeutics
Funding rounds
1 roundsAbout Bold Therapeutics
Developer of novel metallotherapeutics metal-based small molecules designed for the treatment of cancer. The company's lead asset, a ruthenium-based small molecule therapeutic, exhibits significant synergy with the activity of a range of other anti-cancer therapies by disabling critical pathways that support survival and proliferation, enabling doctors to reduce the ability of cancer cells to develop resistance.
- Sector
- Healthcare
- HQ
- Vancouver, Canada
- Founded
- 2018
- Employees
- 20
- Website
- bold-therapeutics.com/
- Ownership
- Privately Held (backing)
Bold Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Bold Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Bold Therapeutics in its N-PORT filings yet. We sweep new filings monthly.